AsthmaMURDOCHNCT04872309
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
An observational study of Asthma and COPD, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Lung magnetic resonance imaging (MRI) with proton and inhaled inert gases has demonstrated a clinical ability to provide valuable structural and functional information in lung disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- How many people
- 160 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Sep 2019to Aug 2027
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Asthma/COPD/COVID-19
Who may be able to join
- Adults aged 18 years or over.
- Physician diagnosis of stable asthma (BTS guideline Step 3 or above).
- Adults aged 18 years or over.
- Stage 3 or stage 4 COPD as defined by GOLD guidelines 2018, (https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf) .
- FEV1:FVC <0.7 (spirometry results).
- FEV1 < 50% predicted (spirometry results). N.B. spirometry results that have been performed as part of a patient's normal clinical care within 6 months of study visit 1 may be used for definition of disease status and inclusion into the study; alternatively if no spirometry result is available it will be performed at visit 1.
Show all 27Show fewer
- Adult over 18
- Proven COVID-19
- Hospitalised/previously hospitalised on ICU requiring CPAP or mechanical ventilation
- Able to give informed consent
- For currently hospitalised participants, or those with significant on-going respiratory problems - Tolerates test inhalation of non-polarised gas according to supervising clinicians' judgement AND SaO2 do not fall below 80%
- Adult over 18
- Proven COVID-19
- Hospitalised/previously hospitalised with a diagnosis of pneumonia (chest X-ray or CT scan consistent with COVID-19 infection)
- Whilst hospitalised had new onset oxygenation impairment defined as:
- An SpO2 ≤93% on room air and/or requiring additional oxygen to maintain satisfactory oxygenation
- Able to give informed consent
- For currently hospitalised participants, or those with significant on-going respiratory problems - Tolerates test inhalation of non-polarised gas according to supervising clinicians judgement AND SaO2 do not fall below 80%
- Adult over 18
- Proven COVID-19
- Not hospitalised for COVID-19
- Able to give informed consent
- Adult over 18
- Proven COVID-19
- Not hospitalised for COVID-19
- Able to give informed consent
- Attended secondary care clinic with on-going symptoms.
Who cannot join
- Recent asthma exacerbation requiring steroids and/or antibiotics in the 6 weeks prior to a study visit.
- Asthma deemed by a physician to be unstable or in an active treatment modification phase.
- Pregnancy (determined by urine pregnancy test for pre-menopausal women at the screening (V1) or eligibility visits (V3, V5).
- Resting blood oxygen saturations (SaO2) < 90% in room air, as measured by oximeter.
- Inability to comfortably lie supine.
- Any contraindication(s) to MRI scanning as per the MRI Screening Form and standard operating procedure used by the Unit of Academic Radiology, Sheffield.
Show all 66Show fewer
- Disease or co-morbidity of sufficient severity as to make survival until 6 year follow up unlikely, as deemed by study clinician.
- COPD patients
- Recent COPD exacerbation requiring steroids and/or antibiotics in the 6 weeks prior to a study visit.
- COPD deemed by a physician to be unstable or in an active treatment modification phase, including the active phase of pulmonary rehabilitation.
- Pregnancy (determined by urine pregnancy test for pre-menopausal women at the screening (V1) or eligibility visits (V3, V5).
- Significant heart failure as assessed by clinician.
- Resting blood oxygen saturations (SaO2) < 90% in room air, as measured by oximeter.
- Inability to comfortably lie supine.
- Any contraindication(s) to MRI scanning as per the MRI questionnaire and standard operating procedure used by the Unit of Academic Radiology, Sheffield.
- Disease or co-morbidity of sufficient severity as to make survival until 6 year follow up unlikely, as deemed by study clinician.
- ICU COVID-19
- No previous diagnosed respiratory disease with the exception of mild asthma, defined as:
- no oral steroids in past year
- -no hospital admissions last year
- max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS
- Pregnancy (determined by urine pregnancy test for pre-menopausal women)
- Significant heart failure as assessed by clinician.
- Resting blood oxygen saturations (SaO2) < 90%, as measured by oximeter at the time of scanning.
- Inability to comfortably lie supine.
- Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI questionnaire and standard operating procedure used by the MRI Unit.
- 6. Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30 mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use). 7. Previous allergy to gadolinium contrast. 8. Significant co-morbidity to make enrolment unsuitable, as deemed by study clinician.
- Moderate/Severe COVID-19
- No previous diagnosed respiratory disease with the exception of mild asthma, defined as:
- no oral steroids in past year
- -no hospital admissions last year
- max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS
- Pregnancy (determined by urine pregnancy test for pre-menopausal women)
- Significant heart failure as assessed by clinician.
- Resting blood oxygen saturations (SaO2) < 90%, as measured by oximeter at time of MRI scanning.
- Inability to comfortably lie supine.
- Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI questionnaire and standard operating procedure used by the MRI Unit.
- Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30 mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use).
- Previous allergy to gadolinium contrast.
- Significant co-morbidity to make enrolment unsuitable, as deemed by study clinician.
- Mild- Non-hospitalised
- No previous diagnosed respiratory disease with the exception of mild asthma, defined as:
- no oral steroids in past year
- -no hospital admissions last year
- max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS
- Pregnancy (determined by urine pregnancy test for pre-menopausal women)
- Significant heart failure as assessed by clinician.
- Resting blood oxygen saturations (SaO2) < 90%, as measured by oximeter.
- Inability to comfortably lie supine.
- Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI questionnaire and standard operating procedure used by the MRI Unit.
- Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30 mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use).
- Previous allergy to gadolinium contrast.
- Significant co-morbidity to make enrolment unsuitable, as deemed by study clinician.
- Non-hospitalised symptomatic (long-COVID group)
- No previous diagnosed respiratory disease with the exception of mild asthma, defined as:
- no oral steroids in past year
- no hospital admissions last year
- max 500mcg per day BDP or 250mcg fluticasone or equivalent ICS
- Pregnancy (determined by urine pregnancy test for pre-menopausal women)
- Significant heart failure as assessed by clinician.
- Resting blood oxygen saturations (SaO2) < 90%, as measured by oximeter at the time of scanning.
- Inability to comfortably lie supine.
- Any contraindication(s) to MRI scanning or Gadolinium contrast agent as per the MRI questionnaire and standard operating procedure used by the MRI Unit.
- Stage 4 or 5 chronic kidney disease, defined by creatinine clearance less than 30 mL/min as estimated by the Cockcroft-Gault equation (due to gadolinium contrast use).
- Previous allergy to gadolinium contrast.
- Significant co-morbidity to make enrollment unsuitable, as deemed by study clinician.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Academic Unit of Radiology, Univeristy of Sheffield
Sheffield, South Yorkshire, S10 2SJ
About this study
Lung magnetic resonance imaging (MRI) with proton and inhaled inert gases has demonstrated a clinical ability to provide valuable structural and functional information in lung disease. Advances in lung MRI methods have led to the STH department handling clinical imaging referrals from local and national respiratory units. Hyperpolarised Xenon-129 gas MRI is now the gold-standard MRI modality used in clinical practice for asthma and COPD in Sheffield.
In this new study, the investigators will use Xenon gas MR imaging and 19F gas MR imaging to obtain physiological, structural, and functional information about patients with known respiratory disease, namely asthma and COPD. Up to 20 patients with asthma and up to 20 patients with COPD will be recruited. Study visits will involve lung function tests and imaging using proton MRI, hyperpolarised xenon gas MRI, and 19F perfluoropropane MRI. After initial baseline assessments, patients will be followed up after 3 and 6 years to investigate the utility of MRI and lung function measurements in tracking disease progression over time.
Read more
In addition, during the COVID-19 pandemic will also be studying the long term effects of this novel disease. The investigators will use Xenon gas MR imaging and pulmonary vascular 1H MR imaging to obtain physiological, structural, and functional information about patients with COVID-19, including hospitalised patients and mild, non-hospitalised COVID-19 patients. Participants may be invited for baseline assessments during the symptomatic phase of the disease and/or be followed up after 6, 12, 24 and 52 weeks (in line with clinical follow up for hospitalised patients) to investigate long term effects of this novel disease.
This novel approach will provide mechanistic insight in to clinical observations such as : (i) why previously healthy patients can respond so poorly to oxygen/ventilation therapy, (ii) why patients respond to proning, and (iii) whether this is caused by alveolar-capillary interstitial changes and /or microvascular clotting in the pulmonary vasculature (leading to V/Q mismatch), and (iv) whether these acute changes lead to long term interstitial lung disease.
Read the detailed description
For asthma and COPD patients, this is a feasibility study to explore the use of gas MRI lung imaging techniques in tracking disease progression over a 6 year time period. Participants will have a baseline MRI scanning session and then be asked to come for repeat scans after 3 and 6 years.
Participants will attend for 3 visits, once at baseline, at 3years and 6 years. Each visit is split over 2 days should occur within one week. This is to ensure eligibility for MRI scanning.
At the eligibility visit the research team discuss study with patient and obtain informed consent. An MRI Screening Form is used to identify any contra-indications to MRI scanning. The participant will be asked further questions about their health, current diagnosis and any current treatments, smoking history, and about any exposure to pollutants either at home or at work. Women will be asked to take a urine pregnancy test, to ensure pregnant women are excluded from the study. The study doctor will perform a brief cardio-respiratory examination to check that it is safe for the patient to undertake the study. At the MRI scanning visit the participant will have a series of MRI scans, firstly using Xenon gas, then after a short break a they will have a second set of scans using 19F perfluoropropane gas. The participant will also undertake some simple lung function tests.
For COVID patients, this is pilot observational study using nationally unique MR imaging methods to investigate the acute and long-term pathophysiology of COVID-19 infection and the resulting changes seen in the lung, pulmonary vasculature and heart of patients with COVID-19 over the course of 12months.
Patients will attend for up to 5 visits. These are at baseline (patient may still be hospitalised, or this may be shortly after discharge) and 6, 12, 24 and 52 weeks post discharge. These visit timelines are designed to match with clinical follow up timelines for hospitalised patients. After the initial approach and consent patients will be screened for eligibility using the MRI scanning checklist. Patients who are still hospitalised or have significant ongoing respiratory problems will undertake a test gas inhalation under close supervision to ensure that this is tolerated prior to MRI scanning. A renal function blood test will be undertaken if required. For some non-hospitalised patients this will require an additional visit.
At the first MRI scanning visit consent will be taken or re-affirmed if taken prior to this visit. Medical history and medication check will be taken and women of child bearing age will undertake a pregancy test. The participant will have a series of MRI scans, firstly using Xenon gas, then after a short break a they will have a proton MRI which includes using gadolinium contrast. The participant will also undertake some simple lung function tests, including spirometry, gas transfer and endoPAT. Lung function tests will only be completed if the patient is non-infectious.
The repeat assessments at 6, 12, 24 and 52 weeks will be the same as the first visit, patients will be contacted prior to their repeat visit to repeat the MRI screening form and confirm eligibility.
- Conditions
- Asthma, COPD, Covid19, Long COVID
- Medical subject headings
- Asthma, Pulmonary Disease, Chronic Obstructive, COVID-19, Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Asthma Patients | Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above). | |
| COPD Patients | Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018) | |
| ICU COVID-19 | Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation) | |
| Moderate/Severe COVID-19 | Adults hospitalised with COVID-19 | |
| Mild- Non-hospitalised COVID-19 | Adult with proven COVID-19 infection, not hospitalised for COVID-19 | |
| Non-hospitalised symptomatic (long-COVID group) | Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms. |
What is being measured
The primary outcome is the main question the study is designed to answer.
%Ventilated volume
a measurement derived from MRI images that quantifies the relative amount of lung that is ventilated, corrected for size.
Measured: 3-6 years for asthma/COPD patients, 3-12months for COVID-19 participants
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2021
- Study start4 Sep 2019
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Why it stopped: COVID arm of study completed, paused while funding sought
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- University of Sheffield
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04872309
- Sponsor's protocol ID
- STH20825
- Acronym
- MURDOCH
- Status last verified
- Apr 2026
- First submitted
- 29 Apr 2021
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
- ClinicalTrials.gov ID
- NCT04872309
- Acronym / sponsor ID
- MURDOCH / STH20825
- Conditions
- Asthma, COPD, Covid19, Long COVID
- Study type
- Observational
- Recruitment status
- SuspendedReason stopped: COVID arm of study completed, paused while funding sought
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Sheffield Teaching Hospitals NHS Foundation TrustUniversity, hospital or other
- Collaborators
- University of Sheffield
- Study start
- 4 Sep 2019 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 4 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung magnetic resonance imaging (MRI) with proton and inhaled inert gases has demonstrated a clinical ability to provide valuable structural and functional information in lung disease. Advances in lung MRI methods have led to the STH department handling clinical imaging referrals from local and national respiratory units. Hyperpolarised Xenon-129 gas MRI is now the gold-standard MRI modality used in clinical practice for asthma and COPD in Sheffield.
In this new study, the investigators will use Xenon gas MR imaging and 19F gas MR imaging to obtain physiological, structural, and functional information about patients with known respiratory disease, namely asthma and COPD. Up to 20 patients with asthma and up to 20 patients with COPD will be recruited. Study visits will involve lung function tests and imaging using proton MRI, hyperpolarised xenon gas MRI, and 19F perfluoropropane MRI. After initial baseline assessments, patients will be followed up after 3 and 6 years to investigate the utility of MRI and lung function measurements in tracking disease progression over time.
In addition, during the COVID-19 pandemic will also be studying the long term effects of this novel disease. The investigators will use Xenon gas MR imaging and pulmonary vascular 1H MR imaging to obtain physiological, structural, and functional information about patients with COVID-19, including hospitalised patients and mild, non-hospitalised COVID-19 patients. Participants may be invited for baseline assessments during the symptomatic phase of the disease and/or be followed up after 6, 12, 24 and 52 weeks (in line with clinical follow up for hospitalised patients) to investigate long term effects of this novel disease.
This novel approach will provide mechanistic insight in to clinical observations such as : (i) why previously healthy patients can respond so poorly to oxygen/ventilation therapy, (ii) why patients respond to proning, and (iii) whether this is caused by alveolar-capillary interstitial changes and /or microvascular clotting in the pulmonary vasculature (leading to V/Q mismatch), and (iv) whether these acute changes lead to long term interstitial lung disease.
Detailed description
For asthma and COPD patients, this is a feasibility study to explore the use of gas MRI lung imaging techniques in tracking disease progression over a 6 year time period. Participants will have a baseline MRI scanning session and then be asked to come for repeat scans after 3 and 6 years.
Participants will attend for 3 visits, once at baseline, at 3years and 6 years. Each visit is split over 2 days should occur within one week. This is to ensure eligibility for MRI scanning.
At the eligibility visit the research team discuss study with patient and obtain informed consent. An MRI Screening Form is used to identify any contra-indications to MRI scanning. The participant will be asked further questions about their health, current diagnosis and any current treatments, smoking history, and about any exposure to pollutants either at home or at work. Women will be asked to take a urine pregnancy test, to ensure pregnant women are excluded from the study. The study doctor will perform a brief cardio-respiratory examination to check that it is safe for the patient to undertake the study. At the MRI scanning visit the participant will have a series of MRI scans, firstly using Xenon gas, then after a short break a they will have a second set of scans using 19F perfluoropropane gas. The participant will also undertake some simple lung function tests.
For COVID patients, this is pilot observational study using nationally unique MR imaging methods to investigate the acute and long-term pathophysiology of COVID-19 infection and the resulting changes seen in the lung, pulmonary vasculature and heart of patients with COVID-19 over the course of 12months.
Patients will attend for up to 5 visits. These are at baseline (patient may still be hospitalised, or this may be shortly after discharge) and 6, 12, 24 and 52 weeks post discharge. These visit timelines are designed to match with clinical follow up timelines for hospitalised patients. After the initial approach and consent patients will be screened for eligibility using the MRI scanning checklist. Patients who are still hospitalised or have significant ongoing respiratory problems will undertake a test gas inhalation under close supervision to ensure that this is tolerated prior to MRI scanning. A renal function blood test will be undertaken if required. For some non-hospitalised patients this will require an additional visit.
At the first MRI scanning visit consent will be taken or re-affirmed if taken prior to this visit. Medical history and medication check will be taken and women of child bearing age will undertake a pregancy test. The participant will have a series of MRI scans, firstly using Xenon gas, then after a short break a they will have a proton MRI which includes using gadolinium contrast. The participant will also undertake some simple lung function tests, including spirometry, gas transfer and endoPAT. Lung function tests will only be completed if the patient is non-infectious.
The repeat assessments at 6, 12, 24 and 52 weeks will be the same as the first visit, patients will be contacted prior to their repeat visit to repeat the MRI screening form and confirm eligibility.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Asthma Patients | – | –Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above). |
| COPD Patients | – | –Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018) |
| ICU COVID-19 | – | –Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation) |
| Moderate/Severe COVID-19 | – | –Adults hospitalised with COVID-19 |
| Mild- Non-hospitalised COVID-19 | – | –Adult with proven COVID-19 infection, not hospitalised for COVID-19 |
| Non-hospitalised symptomatic (long-COVID group) | – | –Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Asthma/COPD/COVID-19
Key inclusion criteria (27 listed)
- Adults aged 18 years or over.
- Physician diagnosis of stable asthma (BTS guideline Step 3 or above).
- Adults aged 18 years or over.
- Stage 3 or stage 4 COPD as defined by GOLD guidelines 2018, (https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf) .
- FEV1:FVC <0.7 (spirometry results).
Key exclusion criteria (66 listed)
- Recent asthma exacerbation requiring steroids and/or antibiotics in the 6 weeks prior to a study visit.
- Asthma deemed by a physician to be unstable or in an active treatment modification phase.
- Pregnancy (determined by urine pregnancy test for pre-menopausal women at the screening (V1) or eligibility visits (V3, V5).
- Resting blood oxygen saturations (SaO2) < 90% in room air, as measured by oximeter.
- Inability to comfortably lie supine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
%Ventilated volume
Time frame: 3-6 years for asthma/COPD patients, 3-12months for COVID-19 participants
a measurement derived from MRI images that quantifies the relative amount of lung that is ventilated, corrected for size.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma and COPD, run by Sheffield Teaching Hospitals NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 27 inclusion and 66 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
%Ventilated volume (time frame: 3-6 years for asthma/COPD patients, 3-12months for COVID-19 participants). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.